APYX Compensation

Apyx Medical Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Published August 07, 2025 at 08:06 PM

CLEARWATER, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical”; the “Company”) today announced that on August 4, 2025, Apyx granted a nonstatuatory stock option to purchase 100,000 shares of common stock to John Featherstone, Apyx’s Vice President, North American Sales as a material inducement to such employee’s employment and in accordance with Nasdaq Listing Rule 5635(c)(4).

Related Questions

Will the grant increase the company’s outstanding share count and affect the float or liquidity of the stock? How does this Nasdaq Listing Rule 5635(c)(4) compliance affect the company’s regulatory standing and investor perception? What insider trading or lock‑up restrictions, if any, are attached to this inducement grant? What are the tax implications for John Featherstone and for Apyx Medical regarding this stock option grant? What impact might the market have on Apyx’s stock price and trading volume in response to this material inducement announcement? How will this non‑statutory stock option issuance affect share dilution and earnings per share (EPS)? When will the options vest and what is the exercise period for the grant? How does this compensation package compare to similar senior sales executive grants at peer companies in the medical device sector? What is the strike price of the 100,000 stock options and how does it compare to the current market price? Could the grant be interpreted as management’s confidence in future sales growth, and how might that influence investor sentiment?